RNA Insider Trade: 107,500-Share Sale via 10b5-1 Plan

Rhea-AI Filing Summary

Arthur A. Levin, a director of Avidity Biosciences (RNA), reported both the exercise of stock options and the sale of shares on 08/06/2025. He exercised options to acquire 107,500 shares at an exercise price of $22.34 per share; the option is noted as fully vested and exercisable. The same 107,500 shares were sold under a Rule 10b5-1 trading plan adopted on October 17, 2024 at a weighted-average price of $47.6175 per share, with trade prices reported in a range of $47.50–$48.02.

Following these transactions the reporting person directly beneficially owned 19,650 shares. The filing also discloses indirect holdings of 131,372 shares through a family trust and 22,500 shares through a charitable remainder trust. The related option shows an expiration date of 02/01/2031.

Positive

• Exercised options to acquire 107,500 shares at $22.34 per share
• Sale executed under a Rule 10b5-1 trading plan adopted on October 17, 2024
• Option underlying the exercised shares is fully vested and exercisable
• Filing discloses weighted-average sale price ($47.6175) and trade price range ($47.50–$48.02)

Negative

• Direct beneficial ownership decreased to 19,650 shares following the reported sale
• Reported sale of 107,500 shares reduced the reporting person’s direct stake

Insights

Financial Analyst

TL;DR: Director exercised 107,500 options and sold 107,500 shares under a pre-established 10b5-1 plan; direct holdings decreased.

The reported transactions consisted of an option exercise to acquire 107,500 shares at $22.34 per share and the contemporaneous sale of 107,500 shares at a weighted-average $47.6175. Sales were executed pursuant to a Rule 10b5-1 plan adopted on October 17, 2024. The option is stated as fully vested and exercisable, and it expires on 02/01/2031. After the transactions the reporting person directly beneficially owns 19,650 shares, with additional indirect holdings in a family trust and a charitable remainder trust. The disclosure is precise on quantities and prices and provides the 10b5-1 context that clarifies the transactions’ pre-planned nature.

Corporate Governance Expert

TL;DR: Transactions executed under a previously adopted 10b5-1 plan; insider transparency is preserved by disclosing plan adoption and weighted-average prices.

The Form 4 discloses that the sales were effected under a Rule 10b5-1 trading plan adopted on October 17, 2024, and provides a weighted-average sale price plus the explicit price range. The filing also notes the exercised option is fully vested and exercisable, and supplies the option expiration date. The report identifies direct and indirect beneficial ownership counts, including trust holdings, which helps stakeholders understand how control and economic interest are distributed following the transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN ARTHUR A

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DRIVE, SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/06/2025		M(1)		107,500	A	$22.34	127,150	D
Common Stock	08/06/2025		S(1)		107,500	D	$47.6175(2)	19,650	D
Common Stock								131,372	I	By family trust
Common Stock								22,500	I	By charitable remainder trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.34	08/06/2025		M(1)			107,500	(3)	02/01/2031	Common Stock	107,500	$0	12,500	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on October 17, 2024.

2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $47.50 to $48.02. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This option is fully vested and exercisable as of the date of this Report.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Avidity (RNA) disclose in this Form 4?

The filing reports that Director Arthur A. Levin exercised 107,500 options at $22.34 per share and sold 107,500 shares on 08/06/2025.

At what price were the shares sold in the reported transactions for RNA?

Shares were sold at a weighted-average price of $47.6175 per share, with individual trade prices reported in the range $47.50–$48.02.

Were the sales part of a pre-arranged trading plan for Avidity insider trades?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 17, 2024.

What was the reporting person’s direct ownership after the transactions?

After the reported transactions the reporting person directly beneficially owned 19,650 shares.

Does the Form 4 disclose indirect holdings for the reporting person?

Yes. The filing shows indirect holdings of 131,372 shares held by a family trust and 22,500 shares held by a charitable remainder trust.

Is the exercised option fully vested and when does it expire?

The Form 4 states the option is fully vested and exercisable and lists an expiration date of 02/01/2031.